International Clinical Trial: mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817888) titled 'mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer' on Sept. 8.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Condition: Phase 2 Study

Intervention: Drug: FOLFOXIRI + Bevacizumab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 30, 2026

Target Sample Size: 119

To know more, visit https://clinicaltrials.gov/study/NCT07817888

Published by HT Digital Conten...